Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer
Neoadjuvant endocrine therapy is a promising alternative for HR-positive breast cancer, especially for patients with poor responses to chemotherapy.
Authors
- Xiuqing Shi (ORCID: https://orcid.org/0000-0002-1240-8818)
- Min Jiang (ORCID: https://orcid.org/0000-0003-1345-9227)
- Mengqi Zhang (ORCID: https://orcid.org/0000-0003-4919-8786)
- Nilupai Abudureheiyimu
- L. Qin
- Jiaxuan Liu (ORCID: https://orcid.org/0000-0002-7937-320X)
- Shihan Zhou
- Lixi Li
- F. C. Ma
- Xue Yang
- Mingxiao Li
- Binghe Xu
- Xiuwen Guan
- Qiao Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1093/oncolo/oyag032
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00